文献速递乳腺癌支持与姑息治疗

地塞米松漱口水(SWISH)预防激素受体阳性、HER2阴性转移性乳腺癌女性依维莫司相关口腔炎:单臂2期试验

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2017-03-15

这项美国多中心单臂2期预防研究纳入92例绝经后激素受体阳性、HER2阴性转移性乳腺癌女性,从第1周期第1天起接受依维莫司10 mg加依西美坦25 mg每日一次,并使用无酒精地塞米松0.5 mg/5 mL口服溶液10 mL漱口。主要终点为8周内2级或更差口腔炎发生率,在85例可评估患者中为2%(95% CI 0.29-8.24),而BOLERO-2历史对照为33%(95% CI 28.8-37.4)。作者认为预防性使用地塞米松口服溶液大幅降低了口腔炎发生率和严重程度,可能成为接受依维莫司和依西美坦治疗患者的新标准口腔护理。

要点

  • 85例可评估患者8周内2级或更差口腔炎发生率为2%(95% CI 0.29-8.24),BOLERO-2历史对照为33%(95% CI 28.8-37.4)。
  • 安全性集92例中,最常见的3级和4级不良事件为高血糖7例(8%)、皮疹4例(4%)、呼吸困难3例(3%)。
  • 92例中20例(22%)报告严重不良事件,其中6例(7%)被认为与治疗相关,最常见为呼吸困难3例(3%)和肺炎2例(2%)。

核心结论

  • 预防性使用地塞米松口服溶液大幅降低了接受依维莫司和依西美坦治疗患者的口腔炎发生率和严重程度,可能成为这些患者新的标准口腔护理。

研究设计与样本

  • 美国多中心单臂2期预防研究,2014年5月28日至2015年10月8日入组92例绝经后激素受体阳性、HER2阴性转移性乳腺癌女性,85例可评估疗效。
  • 患者从第1周期第1天起每日接受依维莫司10 mg加依西美坦25 mg,并使用无酒精地塞米松0.5 mg/5 mL口服溶液10 mL漱口2分钟后吐出,每日四次,持续8周;8周后可由临床医生和患者决定继续使用最多额外8周。
  • 主要终点为8周内2级或更差口腔炎发生率,与BOLERO-2试验中未使用地塞米松漱口预防口腔炎的激素受体阳性晚期乳腺癌患者历史对照比较。

主要发现

  • 8周内2级或更差口腔炎发生率为85例中2例(2%,95% CI 0.29-8.24),BOLERO-2历史对照为482例中159例(33%,95% CI 28.8-37.4)。
  • 安全性集92例中83例(90%)至少发生一次不良事件。
  • 安全性集92例中最常见的3级和4级不良事件为高血糖7例(8%)、皮疹4例(4%)、呼吸困难3例(3%)。
  • 92例中20例(22%)报告严重不良事件,其中6例(7%)被认为与治疗相关,最常见为呼吸困难3例(3%)和肺炎2例(2%)。
  • 92例中12例(13%)因怀疑与治疗相关的不良事件导致停用依维莫司和依西美坦,最常见为皮疹、高血糖和口腔炎,各影响2例(2%)患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and interruptions of everolimus. Anecdotal use of topical steroid oral prophylaxis has been reported in patients with breast cancer. We aimed to assess dexamethasone-based mouthwash for prevention of stomatitis in patients with breast cancer. METHODS: This US-based, multicentre, single-arm, phase 2 prevention study enrolled women aged 18 years and older with postmenopausal status who had histologically or cytologically confirmed metastatic hormone receptor-positive, HER2-negative breast cancer. Beginning on day 1 of cycle 1, patients received everolimus 10 mg plus exemestane 25 mg daily, with 10 mL of alcohol-free dexamethasone 0·5 mg per 5 mL oral solution (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. The primary endpoint was incidence of grade 2 or worse stomatitis by 8 weeks assessed in the full analysis set (patients who received at least one dose of everolimus and exemestane and at least one confirmed dose of dexamethasone mouthwash) versus historical controls from the BOLERO-2 trial (everolimus and exemestane treatment in patients with hormone receptor-positive advanced breast cancer who were not given dexamethasone mouthwash for prevention of stomatitis). This trial is registered at ClinicalTrials.gov, number NCT02069093. FINDINGS: Between May 28, 2014, and Oct 8, 2015, we enrolled 92 women; 85 were evaluable for efficacy. By 8 weeks, the incidence of grade 2 or worse stomatitis was two (2%) of 85 patients (95% CI 0·29-8·24), versus 159 (33%) of 482 patients (95% CI 28·8-37·4) for the duration of the BOLERO-2 study. Overall, 83 (90%) of 92 patients had at least one adverse event. The most frequently reported grade 3 and 4 adverse events in the safety set were hyperglycaemia (seven [8%] of 92 patients), rash (four [4%]), and dyspnoea (three [3%]). Serious adverse events were reported in 20 (22%) patients; six (7%) were deemed treatment related, with dyspnoea (three [3%]) and pneumonia (two [2%]) reported most frequently. 12 (13%) of 92 patients had adverse events suspected to be related to treatment that led to discontinuation of everolimus and exemestane (the most common were rash, hyperglycaemia, and stomatitis, which each affected two [2%] patients). INTERPRETATION: Prophylactic use of dexamethasone oral solution substantially reduced the incidence and severity of stomatitis in patients receiving everolimus and exemestane and could be a new standard of oral care for patients receiving everolimus and exemestane therapy. FUNDING: Novartis Pharmaceuticals Corporation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017. PMID: 28314691. doi:10.1016/S1470-2045(17)30109-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。